Aging Population And Precision Oncology Will Open New Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
17 Aug 25
Updated
17 Aug 25
AnalystHighTarget's Fair Value
SEK 4.50
18.4% overvalued intrinsic discount17 Aug
SEK 5.33
1Y
142.8%7D
18.4%